Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Updating On Novo Nordisk: Still Overvalued
04:05am, Wednesday, 13'th Jul 2022 Seeking Alpha
My previous analysis on Novo Nordisk a few months back showed the company as overvalued and a HOLD. Following 5% drop in today's market, I still rate NVO stock as a hold. Click to know.
Updating On Novo Nordisk: Still Overvalued
12:05am, Wednesday, 13'th Jul 2022
I wrote about Novo Nordisk a few months back, and called the company overvalued and a "Hold". It's time to update that thesis in today's market, and following a 5% drop. The company is still expensive
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint
03:13pm, Tuesday, 12'th Jul 2022 Zacks Investment Research
Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint
12:20pm, Tuesday, 12'th Jul 2022
Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.
Novo Nordisk: EPS Growth With Impressive Relative Strength
11:20am, Tuesday, 12'th Jul 2022
The Health Care sector is seen as a safety trade over recent weeks as global equities sputter. Novo Nordisk has a pipeline of drugs that should support high earnings growth in the coming years.
Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base
03:45pm, Monday, 11'th Jul 2022 Zacks Investment Research
Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.
Beatons Creek Fresh Approvals Update
12:34pm, Monday, 11'th Jul 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) advises that the Chair of the Weste
3 No-Brainer Stocks to Buy in July
10:08am, Saturday, 09'th Jul 2022 The Motley Fool
These stocks appear to be clear winners.
Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why
03:44pm, Friday, 08'th Jul 2022 Zacks Investment Research
Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropath
LabCorp's (LH) Base Testing Volume Grows, Costs Rise
03:31pm, Friday, 08'th Jul 2022 Zacks Investment Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
Here's Why You Should Retain Haemonetics (HAE) Stock For Now
03:14pm, Friday, 08'th Jul 2022 Zacks Investment Research
Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.
Merck (MRK) in Advanced Talks to Buy Seagen (SGEN) Per WSJ
03:58pm, Thursday, 07'th Jul 2022 Zacks Investment Research
Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.
Bruker (BRKR) Debuts NMR Test for Research on Long COVID Risks
03:34pm, Thursday, 07'th Jul 2022 Zacks Investment Research
Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.
My International Portfolio: Making The Best Of The Current Opportunity
07:03am, Thursday, 07'th Jul 2022 Seeking Alpha
My brokerage account portfolio lost almost $19,000 in value since the last update. How do I act during a strong market pullback? Find out.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
05:15pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.
